# TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC

> **NCT03905967** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 336 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** TACE
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT03905967
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-16
- **Primary completion:** 2023-04-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2019-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905967, "TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03905967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*